

U.S.S.N. 08/442,288  
Group Art Unit: 1813

line 15, please underline "Quillaja saponaria molina",  
"its method of" should read --a method for--;  
line 22, please insert a "," after "For example";  
line 24, "protein specific" should read --protein-specific--;  
line 28, please underline "P. falciparum",  
please insert a "," following "linked";  
line 29, please insert a "," following "antigen";  
line 30, "It's" should read --Its--.

At Page 2, line 1, "that is" should read --that it is--;  
line 2, please delete ", in certain animal models";  
line 3, "disease." should read --disease in certain animal  
models.--;  
line 7, "protein specific" should read --protein-specific--;  
line 13, "CTL mediated" should read --CTL-mediated--;  
line 24, "CTL mediated" should read --CTL-mediated--;  
line 26, "based or" should read --based on--;  
line 29, "CTL" should read --CTLs--;  
line 30, please underline "et al.";  
line 31, please underline "P.";  
line 32, please underline "falciparum";  
line 36, "CTL" should read --CTLs--;  
line 37, "molecules" should read --molecule--.

At Page 3, line 18, after "527", please insert -- (1983)--;  
line 34, "this" should read --it--;  
line 35, please delete "In vivo it" and insert "It";  
line 36, after "membranes" please insert "in vivo";  
line 38, "HSV 2" should read --HSV-2--.

At Page 4, line 2, "antibodies" should read --antibody--;  
line 2, "patients" should read --patients'--;

U.S.S.N. 08/442,288  
Group Art Unit: 1813

lines 18 and 24, "rgD2t" should read --rgD<sub>2</sub>t--;  
line 38, please delete "of".

At Page 5, line 2, "HSV 1" should read --HSV-1--;

"HSV 2" should read --HSV-2--;

line 3, "((esp Human) (such as" should read --(esp Human,  
such as--;

line 9, please underline "Salmonella, Neisseria, Borrelia";

line 10, please underline "Chlamydia" and "Bordetella";

line 12, please underline "Toxoplasma";

line 23, please underline "inter alia";

line 32 "3D MPL" should read --3D-MPL--;

line 33 "3D MPL" should read --3D-MPL--.

At Page 6, line 31, "3D MPL" should read --3D-MPL--;

line 34, "3D MPL" should read --3D-MPL--;

line 35, "rgD2T" should read --rgD<sub>2</sub>t--;

At Page 7, lines 5, 6, 7, 9, 15, 17, 23, 25, 29 and 31, "rgD2t" should read  
--rgD<sub>2</sub>t--.

At Page 8, lines 10 and 26, "rgD2t" should read --rgD<sub>2</sub>t--.

At Page 9, line 12, "3D MPL" should read --3D-MPL--;

line 15, "3D MPL" should read --3D-MPL--.

At Page 10, line 1, "S/3 D MPL" should read -- S/3D-MPL--;

line 17, "3D MPL" should read --3D-MPL--;

line 20, "3D MPL" should read --3D-MPL--;

line 36, please underline "in";

line 37, please underline "vitro" and "P. falciparum".

At Page 11, line 29, "supematant" should read --supernatant".

At Page 14, line 5, "Humoral" should read --humoral--;

line 24, "gD2t" should read --rgD<sub>2</sub>t--;

line 32, "rgD2t" should read --rgD<sub>2</sub>t--.